Production (Stage)
Amneal Pharmaceuticals, Inc.
AMRX
$7.16
-$0.03-0.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -13.05M | -116.89M | -184.45M | -174.62M | -168.69M |
| Total Depreciation and Amortization | 240.82M | 236.19M | 226.99M | 225.24M | 226.78M |
| Total Amortization of Deferred Charges | 35.62M | 35.61M | 13.84M | 14.76M | 16.29M |
| Total Other Non-Cash Items | 142.00M | 144.25M | 228.69M | 236.80M | 240.52M |
| Change in Net Operating Assets | -98.47M | -4.07M | 27.78M | -49.73M | -113.44M |
| Cash from Operations | 306.92M | 295.10M | 312.84M | 252.46M | 201.46M |
| Capital Expenditure | -64.40M | -60.34M | -49.67M | -45.03M | -45.46M |
| Sale of Property, Plant, and Equipment | 524.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 11.99M | 11.99M | 4.99M | 4.99M | -- |
| Other Investing Activities | -9.15M | -14.65M | -33.95M | -31.35M | -31.75M |
| Cash from Investing | -61.03M | -63.00M | -78.63M | -71.39M | -77.21M |
| Total Debt Issued | 218.00M | 48.00M | 374.73M | 384.73M | 404.73M |
| Total Debt Repaid | -405.27M | -233.12M | -440.15M | -416.89M | -404.80M |
| Issuance of Common Stock | 1.20M | 1.15M | 1.05M | 837.00K | 479.00K |
| Repurchase of Common Stock | -22.38M | -7.95M | -7.72M | -7.72M | -7.57M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -19.35M | -19.88M | -179.32M | -206.62M | -215.67M |
| Cash from Financing | -227.80M | -211.79M | -251.42M | -245.66M | -222.83M |
| Foreign Exchange rate Adjustments | -1.30M | -999.00K | -58.00K | -366.00K | -867.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 16.78M | 19.31M | -17.26M | -64.96M | -99.45M |